+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030- Product Image
Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889052
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Malignant Mesothelioma Market is characterized by rapid evolution in both scientific innovation and market strategy, requiring senior decision-makers to act decisively amid shifting competitive and regulatory landscapes. This report presents a comprehensive analysis to support strategic planning, investment, and operational excellence across the sector.

Market Snapshot: Malignant Mesothelioma Market Growth Trajectory

The global malignant mesothelioma market grew from USD 834.43 million in 2024 to USD 905.16 million in 2025. Maintaining strong momentum, the market is projected to increase at a CAGR of 8.32%, ultimately reaching USD 1.34 billion by 2030. This expansion is driven by advances in immunotherapeutics, the integration of precision medicine, and continuous improvements in regional healthcare infrastructure. Favorable regulatory policies and investment in oncology further augment market expansion, while regional uptake varies by accessibility, reimbursement framework, and local partnership development.

Scope & Segmentation

This analysis provides in-depth coverage of industry segments, technology developments, and regional variants. The market is segmented as follows:

  • Treatment Types: Chemotherapy regimens (pemetrexed combinations, platinum monotherapy), immunotherapies (Ctla-4 inhibitors, Pd-1 inhibitors), radiotherapy, surgery, and targeted therapies (Egfr inhibitors, mesothelin-targeted agents, Vegf inhibitors)
  • Drug Classes: Antifolates, immune checkpoint inhibitors (Ctla-4, Pd-1, Pd-l1), kinase inhibitors, monoclonal antibodies, platinum compounds
  • Line of Therapy: First line, second line, third line and beyond interventions
  • Routes of Administration: Intraperitoneal, intravenous, and oral applications
  • End Users: Ambulatory surgical centers, hospitals, specialty clinics
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with key countries across Western and Eastern Europe, Middle East, Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, and additional Southeast Asian markets)
  • Company Developments: Activity and trends from industry leaders such as Bristol-Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC, Merck & Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited, and Sanofi S.A.

Key Takeaways for Decision-Makers

  • Malignant mesothelioma’s multifaceted clinical profile drives ongoing innovation in immunotherapeutics, targeted treatments, and surgical approaches, demanding robust cross-functional collaboration.
  • The adoption of real-world evidence, machine learning, and digital health solutions enhances clinical trial efficiency and fine-tunes patient stratification, streamlining market access and post-launch monitoring for therapies.
  • End-user preferences and regional care delivery influence the adoption of first-line versus second-line and subsequent management, reinforcing the need for differentiated go-to-market strategies and responsive distribution models.
  • Leading pharmaceutical organizations leverage alliances and licensing agreements, enabling nimble biotech firms to expedite development timelines and access commercialization infrastructure, thus intensifying competition.
  • Customizing regional market strategies is paramount, as distinct regulatory environments, infrastructure maturity, and payer considerations dictate local uptake and reimbursement prospects.

Tariff Impact on the Malignant Mesothelioma Market

Recent U.S. tariffs on essential pharmaceutical imports have created financial challenges for manufacturers and healthcare providers by elevating supply chain and production costs. Localization strategies, including new partnerships with domestic suppliers, are emerging as a response, although these carry operational risks such as validation delays and increased pricing scrutiny by payers. Companies must balance cost controls with clinical differentiation to safeguard competitive positioning in the face of heightened cost sensitivity.

Methodology & Data Sources

This research applies a blended methodology, combining primary interviews with key opinion leaders and biopharma executives, and reviews regulatory documents, clinical trial registries, and peer-reviewed journals. Quantitative findings are cross-referenced with proprietary databases and validated through data triangulation to ensure accuracy and relevance. Subject matter experts conduct final reviews for unbiased, up-to-date results.

Why This Report Matters

  • Enables senior leaders to anticipate market direction and optimize investment by identifying the most promising therapeutic and commercial opportunities.
  • Provides clear segmentation and actionable insights to support effective go-to-market planning and adapt to regional demands and regulatory shifts.
  • Delivers an evidence-based foundation for stakeholder alignment, streamlining reimbursement negotiations and supporting competitive advantage in a dynamic market environment.

Conclusion

This report provides senior decision-makers with actionable market intelligence and segment insights to navigate the complexities of the malignant mesothelioma landscape. By leveraging these findings, organizations can shape future-focused strategies for growth and patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Malignant Mesothelioma Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Pemetrexed Combinations
8.2.2. Platinum Monotherapy
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.4. Radiotherapy
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Egfr Inhibitors
8.6.2. Mesothelin Targeted Agents
8.6.3. Vegf Inhibitors
9. Malignant Mesothelioma Market, by Drug Class
9.1. Introduction
9.2. Antifolates
9.3. Immune Checkpoint Inhibitors
9.3.1. Ctla-4 Inhibitors
9.3.2. Pd-1 Inhibitors
9.3.3. Pd-l1 Inhibitors
9.4. Kinase Inhibitors
9.5. Monoclonal Antibodies
9.6. Platinum Compounds
10. Malignant Mesothelioma Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line and Beyond
11. Malignant Mesothelioma Market, by Route of Administration
11.1. Introduction
11.2. Intraperitoneal
11.3. Intravenous
11.4. Oral
12. Malignant Mesothelioma Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Malignant Mesothelioma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Malignant Mesothelioma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Malignant Mesothelioma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Eli Lilly and Company
16.3.3. AstraZeneca PLC
16.3.4. Merck & Co., Inc.
16.3.5. F. Hoffmann-La Roche Ltd.
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Novartis AG
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MALIGNANT MESOTHELIOMA MARKET MULTI-CURRENCY
FIGURE 2. MALIGNANT MESOTHELIOMA MARKET MULTI-LANGUAGE
FIGURE 3. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 149. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 150. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 153. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 198. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 225. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 279. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 285. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 288. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 309. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 313. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 316. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 321. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 322. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 324. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 325. INDIA MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Malignant Mesothelioma market report include:
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 905.16 Million
Forecasted Market Value ( USD ) by 2030 $ 1340 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Malignant Mesothelioma Market Report 2025 - Product Image

Malignant Mesothelioma Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 259 Pages
  • Global
From
Malignant Mesothelioma - Global Strategic Business Report - Product Image

Malignant Mesothelioma - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Malignant Mesothelioma Therapeutics Market Report and Forecast 2024-2032 - Product Image

Malignant Mesothelioma Therapeutics Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.